While currently there is no available data comparing these agents, an ongoing trial, HARMONIA (NCT05207709), is comparing the effect of endocrine therapy with either palbociclib or ribociclib in first-line patients with metastatic HR+/HER2- BC with HER2-enriched intrinsic molecular subtype [24]. The gene discussed is ERBB2; the disease is breast cancer.